GSK mRNA Flu Vaccine: Second-Mover Dual-Antigen Bet Needs Phase 3 to Justify Differentiation

GSK's mRNA Flu Vaccine Advances to Phase 3 After Positive Mid-Stage Data

GSK is advancing its mRNA-based flu vaccine candidate to a Phase 3 trial following positive Phase 2 results. The mid-stage study, involving 971 adults, demonstrated superior immune responses compared to licensed inactivated flu vaccines and was generally well tolerated. This move positions GSK to potentially compete in the mRNA flu market, especially after the FDA's recent approval of Moderna's mFLUVISA. The planned Phase 3 trial, set for September, will uniquely target both haemagglutinin (HA) and neuraminidase (NA) antigens, aiming for improved protection against seasonal influenza, which causes 1 billion global cases and up to 650,000 respiratory deaths annually.

• GSK's investigational mRNA-based vaccine showed superior immune responses in a Phase 2 trial involving 971 adults, compared to existing licensed inactivated flu vaccines. Both younger and older adult participants who received GSK's vaccine exhibited higher immune responses. The vaccine was also reported to be generally well tolerated, providing a strong foundation for its progression to late-stage clinical development.
• The upcoming Phase 3 trial will be groundbreaking as the first flu vaccine study to target both haemagglutinin (HA) and neuraminidase (NA) antigens. While current licensed vaccines primarily focus on HA, GSK believes that also targeting NA, which plays a crucial role in viral binding and spread, could significantly enhance protection, reduce illness severity, and limit transmission of the flu virus.
• GSK's advancement comes amidst a resurgence of mRNA vaccine technology, highlighted by the FDA's recent approval of Moderna's mFLUVISA as the first mRNA-based flu vaccine in the U.S. The significant unmet need in influenza, with varying efficacy of current vaccines (e.g., 36% last year), underscores the potential impact of GSK's candidate, which has already received the FDA's Fast Track designation in July.

Addressing the Persistent Challenges in Seasonal Flu Prevention

Current treatment approaches for seasonal influenza face a convergence of clinical, virological, and pharmacological limitations that complicate effective disease management. While neuraminidase inhibitors (NAIs) and the cap-dependent endonuclease inhibitor baloxavir marboxil represent the primary antiviral options, each class carries distinct constraints that affect their utility across patient populations and clinical settings.

• Narrow treatment window: Early antiviral therapy, initiated within 48 hours of symptom onset, is required to reduce morbidity and mortality. This tight window is complicated by the fact that clinical diagnosis is unreliable and virological confirmation can be challenging, delaying treatment initiation in hospitalized adults.

• Antiviral resistance: The H275Y neuraminidase mutation confers resistance to oseltamivir and has been identified in both seasonal H1N1 and 2009 pandemic influenza viruses. During the 2008–2009 season, 93.3% of seasonal H1N1 viruses tested harbored the H275Y mutation and were reported as oseltamivir-resistant. H275Y variants also exhibited reduced susceptibility to peramivir. Although the H275Y mutation leads to a minor reduction in viral fitness, transmission potentials of strains carrying this mutation were comparable in the naïve ferret model, underscoring the epidemiological risk of resistant variant spread.

• Resistance emergence with baloxavir marboxil: Variants with reduced susceptibility to baloxavir marboxil (PA/I38T mutants) were detected in 2.2% of influenza A(H1N1)pdm09 and in 9.7% of influenza A(H3N2) in clinical trials. In pediatric patients specifically, variants with reduced drug susceptibility have been detected in 20%–30% of those treated with baloxavir marboxil.

• Limited evidence in hospitalized and high-risk populations: Current available evidence on antiviral treatment benefits in adult hospitalized patients is essentially based on observational studies, due to the lack of placebo-controlled trials. Controlled clinical trials are urgently needed to evaluate comparative treatment efficacy of different agents and combinations, including emergence of antiviral resistance, and to address issues related to dosage, duration, and parenteral route.

• Reduced vaccine immunogenicity in immunocompromised patients: The immunogenicity of the influenza vaccine is overall reduced in immunocompromised patients, including HIV-infected individuals, solid-organ and stem-cell transplant recipients, and patients receiving biological agents, despite vaccination remaining the primary preventive strategy. The efficacy of novel strategies to improve immunogenicity — such as adjuvanted vaccines, boosting doses, and intradermal vaccination — needs to be validated in appropriately powered clinical trials.

• Differential adverse event profiles limiting drug selection: Oseltamivir predominantly affects the psychiatric system, while baloxavir marboxil primarily impacts the gastrointestinal system. In pediatric populations, oseltamivir-associated adverse event signals were detected across 17 system organ classes, and reports of adverse reactions such as respiratory arrest have been documented for baloxavir marboxil. These distinct safety profiles require individualized treatment decisions, particularly in vulnerable populations.

GSK's Novel HA/NA Targeting and Promising Phase 2 Results

Several key randomized controlled trials evaluated the efficacy, safety, and immunogenicity of seasonal influenza vaccines across distinct study populations and designs. The trials span trivalent and quadrivalent inactivated formulations, live attenuated vaccines, and both adult and pediatric cohorts, with endpoints ranging from culture-confirmed influenza prevention to serological immunogenicity measures.

The Shifting Landscape: mRNA's Impact on Flu Vaccine Development

Over the past five years, the influenza treatment landscape has been shaped by a growing body of evidence evaluating both established and novel antiviral agents. Oseltamivir, a neuraminidase inhibitor (NAI), has long served as the standard of care for severe influenza illness, with the most abundant evidence base across settings including hospital and long-term care facilities, and the strongest evidence for reducing mortality and complications. However, a 2021 randomized clinical trial in low-risk adults demonstrated that while oseltamivir decreased viral shedding — with 45.0% of participants in the oseltamivir arm having virus detected at day 3 versus 57.2% in the placebo arm (absolute difference of -12.2% [-21.4%, -3.0%], P = .010) — it did not significantly decrease the time to resolution of clinical symptoms (median 79.0 hours versus 84.0 hours for placebo, P = .34). Concurrently, a 2025 in vitro and in vivo study found that the EC of oseltamivir was significantly increased in 41 seasonal influenza H1N1 strains from 2023 compared to the 2009 reference strain, with this increase correlated to elevated HA and NA activities, indicating a measurable reduction in oseltamivir efficacy against circulating strains.

Baloxavir marboxil, an endonuclease inhibitor with a novel mechanism of action, has emerged as a clinically relevant alternative and has been evaluated across multiple patient populations. A 2022 meta-analysis of three phase 3 randomized controlled trials enrolling 3,771 patients found that baloxavir had an insignificantly shorter time to alleviation of symptoms compared with oseltamivir (mean difference, -1.29 h; 95% CI, -6.80 to 4.21), but demonstrated a significantly shorter time to alleviation of symptoms versus placebo (mean difference, -26.32 h; 95% CI, -33.78 to -18.86). Baloxavir was associated with a significant decline in influenza virus titers and viral RNA load compared to both oseltamivir and placebo, and showed a lower risk of any adverse events than oseltamivir (OR, 0.82; 95% CI, 0.69-0.98) and placebo (OR, 0.79; 95% CI, 0.66-0.96). A 2021 network meta-analysis of 26 trials (11,897 participants) further indicated that baloxavir was associated with the lowest risk of influenza-related complications (risk ratio, 0.51; 95% CI, 0.32-0.80) and the lowest risk of total adverse events (risk ratio, 0.84; 95% CI, 0.74-0.96) compared with placebo, based on moderate-quality evidence. Pediatric evaluation of baloxavir has also advanced, with an active-controlled trial protocol published in 2021 designed to assess baloxavir versus oseltamivir in Japanese children aged 6 to less than 12 years using the Japanese-approved dose.

Combination antiviral therapy has gained increasing attention as a strategy to improve outcomes and potentially reduce resistance selection. A 2021 comparative effectiveness study in critically ill influenza patients found that favipiravir and oseltamivir combination therapy was associated with higher clinical improvement on day 14 compared to oseltamivir monotherapy (62.5% vs 42.2%; P = .0247), with an adjusted subhazard ratio of 2.06 (95% confidence interval, 1.30-3.26), and a higher proportion of undetectable viral RNA at day 10 (67.5% vs 21.9%; P < .01), though no significant differences were observed in mortality. The 2025 mouse model study of molnupiravir/baloxavir combination demonstrated synergistic inhibitory effects in vitro, and in vivo the combination showed significantly inhibited viral replication, the lowest inflammatory response, and a higher survival rate compared to either monotherapy. A 2022 review of preclinical and clinical developments noted that combination therapy may become an important treatment option to improve patient outcomes in those with severe illness or immunocompromise, and that clinical trials increasingly evaluate drug combinations across a range of patient cohorts.

GSK's Dual-Antigen mRNA Flu Vaccine: A New Frontier in Protection

The landscape of seasonal influenza vaccination is on the cusp of a significant transformation, driven by the advent of mRNA technology. GSK's decision to advance its mRNA-based flu vaccine candidate into Phase 3 trials, particularly with a novel dual-antigen approach targeting both hemagglutinin (HA) and neuraminidase (NA), signals a bold strategic move. This development is set against a backdrop of a substantial global health burden, with influenza responsible for hundreds of thousands of respiratory deaths annually, underscoring the persistent need for more effective preventive measures.

Current influenza vaccines, primarily focused on HA, often face limitations due to the virus's rapid antigenic drift, necessitating annual reformulation and sometimes resulting in suboptimal effectiveness. The inclusion of NA, an antigen for which immune responses independently correlate with protection, represents a promising avenue for broader and potentially more durable immunity. Preclinical studies have shown that HA+NA mRNA vaccines can induce higher levels of neutralizing antibodies and multi-type immune responses, offering a scientific rationale for GSK's differentiated strategy.

However, this ambitious path is not without its considerations. While mRNA vaccines have demonstrated robust immunogenicity, they are also associated with higher rates of solicited adverse reactions, typically mild to moderate, which could impact patient perception and adherence. Furthermore, the ultimate clinical superiority of a dual-antigen mRNA vaccine in preventing influenza disease and reducing mortality in a real-world Phase 3 setting still needs to be definitively proven. The market is also becoming increasingly competitive, with Moderna's HA-only mRNA flu vaccine recently approved. GSK will need to articulate a clear value proposition to drive adoption against established, often lower-cost, traditional vaccines. Nevertheless, if successful, GSK's HA+NA mRNA vaccine could redefine the standard of care for influenza prevention, offering a more comprehensive shield against this pervasive respiratory pathogen.